{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:58:03Z","timestamp":1785448683000,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08027-y","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:49:59Z","timestamp":1784040599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+\/HER2- early breast cancer and eligibility for adjuvant CDK4\/6 inhibitors"],"prefix":"10.1007","volume":"218","author":[{"given":"Santiago","family":"Ter\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Illia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carla","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina L\u00f3pez","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Alva","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"S\u00e1nchez-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"8027_CR1","doi-asserted-by":"publisher","first-page":"104437","DOI":"10.1016\/j.breast.2025.104437","volume":"81","author":"J O\u2019Shaughnessy","year":"2025","unstructured":"O\u2019Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching PA et al (2025) Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+\/HER2- early breast cancer. Breast 81:104437. https:\/\/doi.org\/10.1016\/j.breast.2025.104437","journal-title":"Breast"},{"key":"8027_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377:1836\u20131846. https:\/\/doi.org\/10.1056\/NEJMoa1701830","journal-title":"N Engl J Med"},{"key":"8027_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","volume":"380","author":"JA Sparano","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS et al (2019) Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med 380:2395\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa1904819","journal-title":"N Engl J Med"},{"key":"8027_CR4","doi-asserted-by":"publisher","first-page":"e0185753","DOI":"10.1371\/journal.pone.0185753","volume":"12","author":"D Hequet","year":"2017","unstructured":"Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier M-A, Dubot C et al (2017) Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna\u00ae Test in the management of early-stage breast cancers. PLoS ONE 12:e0185753. https:\/\/doi.org\/10.1371\/journal.pone.0185753","journal-title":"PLoS ONE"},{"key":"8027_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","volume":"19","author":"HO Ohnstad","year":"2017","unstructured":"Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT et al (2017) Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res 19:120. https:\/\/doi.org\/10.1186\/s13058-017-0911-9","journal-title":"Breast Cancer Res"},{"key":"8027_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdt494","volume":"25","author":"M Gnant","year":"2014","unstructured":"Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z et al (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339\u2013345. https:\/\/doi.org\/10.1093\/annonc\/mdt494","journal-title":"Ann Oncol"},{"key":"8027_CR7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1200\/JCO.19.00945","volume":"37","author":"F Andre","year":"2019","unstructured":"Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W et al (2019) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update\u2014Integration of Results From TAILORx. JCO 37:1956\u20131964. https:\/\/doi.org\/10.1200\/JCO.19.00945","journal-title":"JCO"},{"key":"8027_CR8","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M et al (2015) Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdv221","journal-title":"Ann Oncol"},{"key":"8027_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41523-022-00423-z","volume":"8","author":"C Lundgren","year":"2022","unstructured":"Lundgren C, Bendahl P-O, Church SE, Ekholm M, Fern\u00f6 M, Forsare C et al (2022) PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients. Npj Breast Cancer 8:61. https:\/\/doi.org\/10.1038\/s41523-022-00423-z","journal-title":"Npj Breast Cancer"},{"key":"8027_CR10","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/jcm13175328","volume":"13","author":"E Esin","year":"2024","unstructured":"Esin E, Yildirim HC, Oksuzoglu B, Markoc F, Guntekin S, Bilgetekin I et al (2024) Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study. JCM 13:5328. https:\/\/doi.org\/10.3390\/jcm13175328","journal-title":"JCM"},{"key":"8027_CR11","doi-asserted-by":"publisher","first-page":"103475","DOI":"10.1016\/j.esmoop.2024.103475","volume":"9","author":"HO Ohnstad","year":"2024","unstructured":"Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H et al (2024) Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer\u2014a prospective national multicentre study (EMIT-1). ESMO Open 9:103475. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103475","journal-title":"ESMO Open"},{"key":"8027_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5","journal-title":"Lancet Oncol"},{"key":"8027_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D et al (2024) Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 390:1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2305488","journal-title":"N Engl J Med"},{"key":"8027_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41523-025-00726-x","volume":"11","author":"S Ladoire","year":"2025","unstructured":"Ladoire S, Kamga AM, Galland L, Reda M, Desmoulins I, Mayeur D et al (2025) Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and\/or ribociclib. Npj Breast Cancer 11:10. https:\/\/doi.org\/10.1038\/s41523-025-00726-x","journal-title":"Npj Breast Cancer"},{"key":"8027_CR15","doi-asserted-by":"publisher","first-page":"105304","DOI":"10.1016\/j.esmoop.2025.105304","volume":"10","author":"P Tarantino","year":"2025","unstructured":"Tarantino P, Rugo HS, Curigliano G, O\u2019Shaughnessy JA, Janni W, Jhaveri K et al (2025) Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+\/HER2 \u2013 early breast cancer: a United States Electronic Health Records database analysis. ESMO Open 10:105304. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105304","journal-title":"ESMO Open"},{"key":"8027_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/jnci\/djaf031","volume":"117","author":"L Arecco","year":"2025","unstructured":"Arecco L, Blondeaux E, Bruzzone M, Arpino G, De Angelis C, De Laurentiis M et al (2025) Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI: J Natl Cancer Inst 117:1198\u20131208. https:\/\/doi.org\/10.1093\/jnci\/djaf031","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"8027_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D et al (2024) Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22:331\u2013357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035","journal-title":"J Natl Compr Canc Netw"},{"key":"8027_CR18","doi-asserted-by":"publisher","unstructured":"Teran S, Bianchi MA, Tolosa P, Rey-Cardenas M, Madariaga A, Lema L et al (2023) Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer. Breast S0960977623005325. https:\/\/doi.org\/10.1016\/j.breast.2023.07.009","DOI":"10.1016\/j.breast.2023.07.009"},{"key":"8027_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.annonc.2021.12.004","volume":"33","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ et al (2022) Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol 33:234\u2013238. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.004","journal-title":"Ann Oncol"},{"key":"8027_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32:1216\u20131235. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023","journal-title":"Ann Oncol"},{"key":"8027_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41523-025-00738-7","volume":"11","author":"M-B Jensen","year":"2025","unstructured":"Jensen M-B, Nielsen TO, Bartlett J, L\u00e6nkholm A-V, Shepherd L, Ejlertsen B (2025) Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer. Npj Breast Cancer 11:26. https:\/\/doi.org\/10.1038\/s41523-025-00738-7","journal-title":"Npj Breast Cancer"},{"key":"8027_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41523-021-00297-7","volume":"7","author":"JMS Bartlett","year":"2021","unstructured":"Bartlett JMS, Bayani J, Kornaga E, Xu K, Pond GR, Piper T et al (2021) Comparative survival analysis of multiparametric tests\u2014when molecular tests disagree\u2014A TEAM Pathology study. Npj Breast Cancer 7:90. https:\/\/doi.org\/10.1038\/s41523-021-00297-7","journal-title":"Npj Breast Cancer"},{"key":"8027_CR23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/annonc\/mdv215","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E et al (2015) Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol 26:1685\u20131691. https:\/\/doi.org\/10.1093\/annonc\/mdv215","journal-title":"Ann Oncol"},{"key":"8027_CR24","doi-asserted-by":"publisher","unstructured":"Pistilli B, Lohrisch C, Shead DA, Fleming GF (2022) Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer. American Soc Clin Oncol Educ Book 42:60\u201372. https:\/\/doi.org\/10.1200\/EDBK_350358","DOI":"10.1200\/EDBK_350358"},{"key":"8027_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Th\u00fcrlimann B et al (2016) Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. JCO 34:927\u2013935. https:\/\/doi.org\/10.1200\/JCO.2015.62.3504","journal-title":"JCO"},{"key":"8027_CR26","doi-asserted-by":"publisher","first-page":"viii68","DOI":"10.1093\/annonc\/mdy270.208","volume":"29","author":"N Hajjaji","year":"2018","unstructured":"Hajjaji N, Robin YM, Bertin D, Bonneterre JM (2018) Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy. Ann Oncol 29:viii68. https:\/\/doi.org\/10.1093\/annonc\/mdy270.208","journal-title":"Ann Oncol"},{"key":"8027_CR27","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, Galv\u00e1n P, Fern\u00e1ndez A, Gaba L et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24:S26\u201335. https:\/\/doi.org\/10.1016\/j.breast.2015.07.008","journal-title":"Breast"},{"key":"8027_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al (2009) Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. JCO 27:1160\u20131167. https:\/\/doi.org\/10.1200\/JCO.2008.18.1370","journal-title":"JCO"},{"key":"8027_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-020-0148-0","volume":"6","author":"M-B Jensen","year":"2020","unstructured":"Jensen M-B, L\u00e6nkholm A-V, Balslev E, Buckingham W, Ferree S, Glavicic V et al (2020) The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. Npj Breast Cancer 6:7. https:\/\/doi.org\/10.1038\/s41523-020-0148-0","journal-title":"Npj Breast Cancer"},{"key":"8027_CR30","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2024.08.233","volume":"35","author":"K Jhaveri","year":"2024","unstructured":"Jhaveri K, Pegram M, Neven P, Curigliano G, Spring LM, Gligorov J et al (2024) 292P Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+\/HER2\u2013 early breast cancer (EBC) from US electronic health records (EHR). Ann Oncol 35:S337\u2013S338. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.233","journal-title":"Ann Oncol"},{"key":"8027_CR31","doi-asserted-by":"publisher","first-page":"oyaf061","DOI":"10.1093\/oncolo\/oyaf061","volume":"30","author":"J Canzian","year":"2025","unstructured":"Canzian J, Gentile D, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M et al (2025) Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients. Oncologist 30:oyaf061. https:\/\/doi.org\/10.1093\/oncolo\/oyaf061","journal-title":"Oncologist"},{"key":"8027_CR32","doi-asserted-by":"publisher","unstructured":"Tarantino P, Rugo HS, Curigliano G, O\u2019Shaughnessy J, Janni W, Jhaveri K et al (2025) Abstract P2-12-02: Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+\/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database. Clin Cancer Res 31. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-P2-12-02.","DOI":"10.1158\/1557-3265.SABCS24-P2-12-02"},{"key":"8027_CR33","doi-asserted-by":"publisher","first-page":"e12062","DOI":"10.1200\/JCO.2017.35.15_suppl.e12062","volume":"35","author":"CA Rodriguez","year":"2017","unstructured":"Rodriguez CA, Garcia-Mu\u00f1oz M, Sancho M, Garcia-Gonzalez M, Delgado C, De Soto D et al (2017) Impact of the Prosigna (PAM50) assay on adjuvant clinical decision making in patients with early stage breast cancer: Results of a prospective multicenter public program. JCO 35:e12062\u2013e12062. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e12062","journal-title":"JCO"},{"key":"8027_CR34","doi-asserted-by":"publisher","first-page":"105521","DOI":"10.1016\/j.esmoop.2025.105521","volume":"10","author":"C Corti","year":"2025","unstructured":"Corti C, Chu X, Exman P, Kline DM, Priedigkeit NM, Mayer EL et al (2025) Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive\/HER2-negative breast cancer: a single-center prospective observational study. ESMO Open 10:105521. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105521","journal-title":"ESMO Open"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08027-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:03:21Z","timestamp":1785445401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08027-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8027"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08027-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Ethics Committee of Hospital Universitario 12 de Octubre.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.T. has received travel grants from Novartis and Leo Pharma. M.I. Declares no conflict of interest. M.C.Q. Declares no conflict of interest. M.L.M. Declares no conflict of interest. M.A.B. has received a speaker honorarium from Novartis, Pfizer, Lilly, Gilead, and AstraZeneca. L.L. Declares no conflict of interest. C.G. Declares no conflict of interest. P.T. is a consultant or played an Advisory Role in AstraZeneca, Daiichi-Sankyo, Novartis, Roche, Adamed, and Seagen, Speaker honorarium: Pfizer, MSD, Novartis, Lilly, AstraZeneca, Daiichi-Sankyo, and Seagen, Travel grants: Pfizer, AstraZeneca, Novartis, and GSK, and Research funding: Seagen. A.M. has received honoraria from AstraZeneca, Clovis, GSK, MSD, and PharmaMar. L.M. has received a speaker honorarium from Novartis. Y.R. Declares no conflict of interest. L.P. Declares no conflict of interest. M.A.C. Declares no conflict of interest. E.C. has received research grants from Roche and has received a speaker honorarium and Advisory Board meetings from Astra Zeneca-Daiichi-Sankyo, Roche, Pfizer, Novartis, MSD, Lilly, Gilead, and does not own stocks in any company. R.S.B. has received honoraria as a speaker: Novartis, AstraZeneca, MSD, Lilly, GSK, Clovis, Seagen, Pfizer, Roche, and Gilead Oncology, Advisory fees: Novartis, Lilly, GSK, Seagen, and Roche, and Non-financial disclosure: ESMO Young Oncologists Committee Member and Scientific Secretary of the Spanish Society of Medical Oncology.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"12"}}